Back

SK Biopharmaceuticals CEO buys 1,000 shares after FDA clinical hold

Verifying
  • SK Biopharmaceuticals CEO Lee Dong-hoon bought additional company shares after the FDA imposed a partial clinical hold.
  • 1,000 shares cost 78.8 million won, while his total holdings rose to 6,000 shares.
  • OPCALIM’s RISE2 enrollment stopped, while fully enrolled RISE3 remains scheduled for second-half results.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.
SK Biopharmaceuticals CEO buys 1,000 shares after FDA clinical hold - CoinPost Terminal